The study was fully enrolled with 928 patients in September 2016. This study milestone occurred in late April 2020. The success of this therapy was statistically significant at a 95% level. All adjustments have been reflected in the accompanying financial statements. The work was performed in the laboratory of Dr. Subbarao. CEL-SCI's lease on the manufacturing facility expires on October 31, 2028. See Item 2 of this report for more information concerning the terms of this lease. Such off-label uses are common across medical specialties. CEL-SCI will require substantial additional capital to remain in operation. However, the development of this technology is in a preliminary stage. CEL-SCI commenced the Phase 3 clinical trial for Multikine in December 2010. CEL-SCI's current and future clinical trials may not be successful. In addition, there is a natural transition period when a new CRO commences work. The pace of change continues to accelerate. CEL-SCI's Board of Directors is not obligated to declare a dividend. CEL-SCI is now in the phase that involves final analysis of the trial results. As of September 30, 2019, Ergomed held 198,000 shares. The timing of these obligations cannot be determined at this time. There can be no assurances that CEL-SCI will be successful in raising additional funds. Mr. Kersten has been with CEL-SCI since 1987. 55 Eyal Talor, Ph.D. joined CEL-SCI in October 1993. For the following 25 years, he continued on at NIH as a guest worker. Robert Watson has been a director of CEL-SCI since December 2017. A summary description of these Plans follows. In some cases these Plans are collectively referred to as the "Plans". A member of the Committee may be removed at any time by action of the Board of Directors. Suite 802Vienna, VA 22182 573,971 1.5% Daniel H. Zimmerman, Ph. The shares are subject to the conditions of Rule 144 under the Securities Act of 1933. 4(f) 2014 Incentive Stock Bonus Plan Filed with this Amendment No. The Phase 3 study is in the final statistical analysis phase. The Company will continue to remain blinded to the study results throughout this process. Forfeitures are accounted for when they occur. At times, these accounts may exceed federally insured limits. The Company has not experienced any losses in such bank accounts. This standard will be effective for the Company on October 1, 2021. The warrants were valued at approximately $211,000 on the date of expiration. The Series XX and YY warrants qualified for equity treatment in accordance with ASC 815. No options were issued to consultants during the year ended September 30, 2020. On the grant date, the options were valued using a Monte Carlo Simulation approach. The Company generally applies the income approach to determine fair value. I have reviewed this annual report on Form 10-K of CEL-SCI Corporation; & & 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES WARRANTS AND NON-EMPLOYEE OPTIONS 4. WARRANTS AND NON-EMPLOYEE OPTIONS PLANT, PROPERTY AND EQUIPMENT 5. 115.\\OK7 M3[26\\O+A(+)=SR.V HJ&[:L"U_#7#*OB+H/A56AN)C=7N.+ @L/\\ /1? Y\\9V]C&5;[); MJK$\'D,Q)P?PQ^=5F5O8NYSU_@/,8))(KB.6)BCJP*L.H-?:&FS-=:3:7#?? The Company’s lease portfolio includes both finance and operating leases. In some cases, these Plans are collectively referred to as the “Plans”. Grant income under the arrangements is recognized when costs are incurred. & The Company considers such valuations to be significant estimates. & The remaining $5.8 million will be e
